Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.

Abstract

Congenital plasminogen deficiency is caused by mutations in PLG, the gene coding for production of the zymogen plasminogen, and is an ultrarare disorder associated with abnormal accumulation or growth of fibrin-rich pseudomembranous lesions on mucous membranes. Left untreated, these lesions may impair organ function and impact quality of life. Plasminogen replacement therapy should provide an effective treatment of the manifestations of congenital plasminogen deficiency. An open-label phase 2/3 study of human Glu-plasminogen administered IV at 6.6 mg/kg every 2 to 4 days in 15 patients with congenital plasminogen deficiency is ongoing. Reported here are data on 14 patients who completed at least 12 weeks of treatment. The primary end point was an increase in trough plasminogen activity levels by at least an absolute 10% above baseline. The secondary end point was clinical success, defined as ≥50% improvement in lesion number/size or functionality impact from baseline. All patients achieved at least an absolute 10% increase in trough plasminogen activity above baseline. Clinical success was observed in all patients with clinically visible (conjunctiva and gingiva), nonvisible (nasopharynx, bronchus, colon, kidney, cervix, and vagina), and wound-healing manifestations of the disease. Therapeutic effects were rapid, as all but 2 lesions resolved or improved after 4 weeks of treatment. Human Glu-plasminogen was well tolerated in both children and adults. This study provides critical first evidence of the clinical utility of ongoing replacement therapy with human Glu-plasminogen for the treatment of children and adults with congenital plasminogen deficiency. This trial was registered at www.clinicaltrials.gov as #NCT02690714.

• Authors: Amy D Shapiro, Charles Nakar, Joseph M Parker, Gary R Albert, John E Moran, Karen Thibaudeau, Neelam Thukral, Brandon M Hardesty, Pierre Laurin, Per Morten Sandset
• Journal: Blood (Blood) Vol. 131 Issue 12 Pg. 1301-1310 (03 22 2018) ISSN: 1528-0020 [Electronic] United States
• PMID: 29321155 (Publication Type: Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: © 2018 by The American Society of Hematology.

Chemical References

• Plasminogen

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Blood Coagulation Disorders, Inherited (blood, drug therapy)
• Child
• Child, Preschool
• Female
• Humans
• Male
• Middle Aged
• Plasminogen (administration & dosage, deficiency, pharmacokinetics)